Jazz Pharmaceuticals (FRA:J7Z) Ending Cash Position : €1,328 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Ending Cash Position?

Jazz Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 was €1,328 Mil.

Jazz Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2023 (€1,252 Mil) to Dec. 2023 (€1,381 Mil) but then declined from Dec. 2023 (€1,381 Mil) to Mar. 2024 (€1,328 Mil).

Jazz Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 (€523 Mil) to Dec. 2022 (€832 Mil) and increased from Dec. 2022 (€832 Mil) to Dec. 2023 (€1,381 Mil).

Jazz Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Jazz Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Ending Cash Position Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

573.61

869.49

523.43

832.12

1,381.29

Jazz Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															1,090.83	1,183.57	1,251.54	1,381.29	1,327.91

Jazz Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Jazz Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	808.319	+	572.967
	=	1,381

Jazz Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1385.805	+	-57.891
	=	1,328

Jazz Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines